Rivaroxaban in Chinese children with giant coronary artery aneurysms after Kawasaki disease
The 15-mg-equivalent rivaroxaban regimen appeared feasible in Chinese children with GCAA after KD, with no GCAA thrombosis, major bleeding or CRNM bleeding observed within 6 months. Larger studies are required to confirm these preliminary findings.
Authors
- Qingfeng He (ORCID: https://orcid.org/0000-0001-5795-1550)
- Lu Zhao (ORCID: https://orcid.org/0000-0002-3950-8595)
- Xue‐cun Liang
- Lan He (ORCID: https://orcid.org/0000-0001-7464-3250)
- B Liu
- Leonardo Rodrigues Brandão (ORCID: https://orcid.org/0000-0001-7711-4530)
- Yuanzheng Zheng
- Feng Wang (ORCID: https://orcid.org/0000-0003-2656-1386)
- Fang Liu (ORCID: https://orcid.org/0000-0003-4841-8206)
- Chu Chen (ORCID: https://orcid.org/0000-0003-2267-8050)
- Guoying Huang (ORCID: https://orcid.org/0000-0001-6002-2226)
- Yixiang Lin
- Qu‐ming Zhao (ORCID: https://orcid.org/0000-0003-3011-3332)
- Shuna Sun
- Xiao Dong Zhu (ORCID: https://orcid.org/0000-0003-0899-5180)
- Guangan Dai
Institutions
- National Medical Products Administration (CN)
- Fudan University (CN)
- Hospital for Sick Children (CA)
- Children's Hospital of Fudan University (CN)
Publication Details
- Journal
- Research and Practice in Thrombosis and Haemostasis
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1016/j.rpth.2025.103211
- Primary Topic
- Kawasaki Disease and Coronary Complications
- Type
- article
- Field-Weighted Citation Impact
- 0.00